Background: Both obesity and smoking are common in schizophrenia patients taking
clozapine, causing cardiovascular disease and premature deaths. Methods: Two hundred …

Objective Clozapine is the first choice in drug-resistant schizophrenia but also causes
important weight changes. This might discourage clinicians who are concerned about the …

Individuals with schizophrenia have standardised mortality rates which are double that of the
general population. In addition to suicide, high rates of cardiovascular and respiratory …

Objective: The aim of this study was to assess the prevalence and magnitude of weight
changes pre-and post-clozapine and to explore the ability of demographic and clinical …

Introduction: Schizophrenia is a chronic mental disorder, and treatment is based on the use
of antipsychotics, such as clozapine. These drugs have been associated with obesity and …

Background Metabolic syndrome is an important side effect associated with clozapine. It has
been hypothesized that weight gain contributes to the development of metabolic syndrome …

Objectives: Patients with schizophrenia are known to be at higher risk than the general
population of cardiovascular disease. Clozapine has been associated in the literature with …

Background To investigate the association of clozapine treatment and weight gain, we
studied short-and long-term weight gain, correlation of weight gain with treatment response …

Method: This study is a retrospective cohort study combining a cross-sectional survey of
metabolic syndrome and retrospective chart review. The subjects were hospitalized …

Objectives Weight gain on clozapine is highly variable and poorly predictable. Its
mechanisms are not well understood. This study explores the factors that predict weight gain …